Jump to main content

The information in the site you are about to see is intended for US healthcare professionals only. Visit Patient Site.


Explore GATTEX (teduglutide) resources to help get your patients started, help eligible patients cover the cost of treatment, and more

OnePath logo


At OnePath, we tailor our product support to your patient

When you prescribe GATTEX for your patient, OnePath is here to provide them dedicated support. We'll connect your patient with a OnePath specialist who acts as their go-to person. They will:

Work with your patient’s insurance provider to
help them receive their prescribed Takeda

Enroll patients in the OnePath Co-Pay
Assistance Program, if they qualify*

Coordinate the shipment and delivery of your
patient’s medication by working with a
specialty pharmacy

Arrange for a trained nursing professional to
teach your patient (or patient's caregiver) how to prepare and inject GATTEX at home, once requested by your office

Provide ongoing support to your patient
throughout their GATTEX treatment journey,
which includes directing them to educational
resources and much more

Download this guide to learn more
about the full OnePath journey.

*To be eligible, patients must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.

If you have questions, call OnePath at 1-866-888-0660, Monday through Friday, 8:30AM to 8:00PM ET

Meet the OnePath product support team

When your patient enrolls in OnePath, they’ll have 3 knowledgeable, dedicated specialists to turn to.

Onboarding and Access Specialist (OAS)

Your patient’s main contact during the first 6-12 months of treatment is their Onboarding and Access Specialist (OAS). The OAS is a local OnePath resource who can meet with your patient virtually, or in person at their home or another convenient location. Your patient’s OAS is here to:

  • Help your patient get started on GATTEX
  • Educate your office about prior authorizations, reauthorizations, and appeals

Patient Support Manager (PSM)

Your patient's contact during OnePath enrollment and for ongoing support is a Patient Support Manager (PSM). Their PSM will:

  • Enroll your patient in the OnePath Co-Pay Assistance Program, if they qualify*
  • Direct your patient to community support resources and advocacy organizations
  • Address your patient’s questions and concerns, and help determine next steps when needed

*To be eligible, patients must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.

Specially trained Nurse Educators

OnePath will arrange for a specially trained Nurse Educator to provide no-cost, in-home, administration training for patients and caregivers.

These dedicated OnePath specialists are never more than a tap or a phone call away. Contact OnePath at 1-866-888-0660, Monday-Friday, 8:30 AM to 8:00 PM ET

Onboarding Guide

OnePath Onboarding and Access Specialist Overview

Download this guide for more information about Onboarding & Access Specialists

Visit OnePath.com
OnePath Guide

OnePath Product Support Program

At OnePath, we tailor our support to your patient. Explore how we get to know your patient, understand who they are, and learn what's most important to them, so we can focus on what they need to access their Takeda medication.


Office Support

Support materials for you and your office

Virtual Booth

GATTEX Virtual Booth

Guide yourself through this virtual booth experience. See how GATTEX works, engage with clinical data, and discover what your patients with short bowel syndrome (SBS) can expect with GATTEX.

Explore Our Booth
GATTEX Starter Kit

HCP Office Starter Kit

The clinician’s guide for getting patients started on GATTEX includes detailed, step-by-step instructions for using the Start Form.

GATTEX Weaning and PS Support Guide

Weaning Parenteral Support (PS) While on GATTEX

View the multi-step process used in GATTEX studies to help both adult and pediatric SBS patients wean off PS.

Review the Process
Dosing and Diagnosis Code Reference

Dosing and Diagnosis Code Reference

Refer to this document for common diagnosis codes for SBS, as well as the recommended dosage of GATTEX for adult and pediatric patients.

See Code Reference
Patient Expectation Guide

Setting Expectations for Your Patients on GATTEX

Download a handbook on navigating a patient's treatment journey with GATTEX—including some of the most important considerations during the first year of treatment—with resources for both your practice and your patients.

Get the Guide
Instructions for Use

Instructions for Use

Patients should review these Instructions for Use before they start using GATTEX and each time they get a refill. It shows how to prepare GATTEX, administer it, and more.

View Instructions
Spanish Prescribing Information

Spanish Prescribing Information

Información de prescripción en español.

GATTEX specialty pharmacy

Specialty Pharmacy

GATTEX is provided to patients who are prescribed GATTEX through a limited distribution specialty pharmacy network. For more information about GATTEX distribution, please call 1-866-888-0660.

Diagnosis Codes

Commonly used ICD-11 and ICD-10 codes for short bowel syndrome (SBS)1

ICD-11 codes


Short bowel syndrome in neonate


Short bowel syndrome

ICD-10 codes


Diseases of the digestive system


Intraoperative and postprocedural complications and disorders of the digestive system, not elsewhere classified


Postsurgical malabsorption, not elsewhere classified, postsurgical blind loop syndrome

Find information you need to know about starting your appropriate patients on GATTEX, including safety assessments, instructions for the Start Form, and more.


  1. Centers for Disease Control and Prevention. ICD-10-CM TABULAR LIST of DISEASES and INJURIES. National Center for Health Statistics. https://ftp.cdc.gov/pub/health_statistics/nchs/publications/ICD10CM/2019/icd10cm_tabular_2019.pdf. Accessed July 23, 2019.
Close Minimize Expand

GATTEX® (teduglutide) for injection is indicated for the treatment of adults and pediatric patients 1 year of age and older with short bowel syndrome (SBS) who are dependent on parenteral support.


Warnings and Precautions
GATTEX has been associated with acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication. Click here for additional Safety Information.

GATTEX® (teduglutide) for injection is indicated for the treatment of adults and pediatric patients 1 year of age and older with short bowel syndrome (SBS) who are dependent on parenteral support.


Warnings and Precautions

Acceleration of neoplastic growth
Colorectal polyps were identified during clinical trials. There is a risk for acceleration of neoplastic growth. In adults, within 6 months prior to starting treatment with GATTEX, colonoscopy of the entire colon with removal of polyps should be performed and follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of GATTEX. Subsequent colonoscopies should be performed every 5 years or more often as needed.

In children and adolescents, perform fecal occult blood testing prior to initiating treatment with GATTEX. Colonoscopy/sigmoidoscopy is required if there is unexplained blood in the stool. Perform subsequent fecal occult blood testing annually in children and adolescents while they are receiving GATTEX. Colonoscopy/sigmoidoscopy is recommended for all children and adolescents after 1 year of treatment, every 5 years thereafter while on continuous treatment with GATTEX, and if they have new or unexplained gastrointestinal bleeding.

In case of intestinal malignancy (GI tract, hepatobiliary, pancreatic), discontinue GATTEX. The clinical decision to continue GATTEX in patients with non-gastrointestinal malignancy should be made based on benefit-risk considerations.

Intestinal obstruction
Intestinal obstruction has been reported in clinical trials and postmarketing. In patients who develop intestinal or stomal obstruction, GATTEX should be temporarily discontinued pending further clinical evaluation and management.

Biliary and pancreatic disease
Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical trials and postmarketing. Laboratory assessment (bilirubin, alkaline phosphatase, lipase, amylase) should be obtained within 6 months prior to starting GATTEX. Subsequent laboratory tests should be done every 6 months or more often as needed. If clinically meaningful changes are seen, further evaluation is recommended including imaging, and continued treatment with GATTEX should be reassessed.

Fluid imbalance and fluid overload
Fluid overload and congestive heart failure have been observed in clinical trials. If fluid overload occurs, especially in patients with underlying cardiovascular disease, parenteral support should be adjusted and GATTEX treatment reassessed. If significant cardiac deterioration develops while on GATTEX, continued GATTEX treatment should be reassessed.

Discontinuation of treatment with GATTEX may also result in fluid and electrolyte imbalance. Fluid and electrolyte status should be monitored in patients who discontinue treatment with GATTEX.

Increased absorption of concomitant oral medication
In clinical trials, one patient receiving prazepam concomitantly with GATTEX experienced dramatic deterioration in mental status progressing to coma during first week of GATTEX therapy. Patients receiving concomitant oral drugs requiring titration or with a narrow therapeutic index should be monitored for adverse reactions due to potential increased absorption of the concomitant drug. The concomitant drug may require a reduction in dosage.

Adverse Reactions
The most common adverse reactions (≥ 10%) with GATTEX are abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload, and hypersensitivity.

Use in Specific Populations
Breastfeeding is not recommended during treatment with GATTEX.

Please click here for full Prescribing Information or Información de prescripción en español.